keyword
https://read.qxmd.com/read/38450178/protective-effects-of-azilsartan-against-cyclophosphamide-induced-ovarian-toxicity-in-rats-model
#1
JOURNAL ARTICLE
Naza Mohammed Ali Mahmood
BACKGROUND: Cyclophosphamide (CP) is an effective alkylating anticancer agent that is widely used in cancer chemotherapy, and it can cause ototoxicity and infertility in women. OBJECTIVES: So, this study aimed to evaluate the protective effects of Azilsartan (AZ) as an antioxidant and anti-inflammatory agent in a rat model of CP-induced ovarian toxicity. MATERIALS AND METHODS: After receiving the 28 female Wister rats, they were acclimatized in proper environmental conditions for a week and then randomly divided into four groups based on the study protocol...
April 2024: Toxicology Research
https://read.qxmd.com/read/38333313/effect-of-azilsartan-on-clinical-blood-pressure-reduction-compared-to-other-angiotensin-receptor-blockers-a-systematic-review-and-meta-analysis
#2
REVIEW
Qaisar Ali Khan, Shalini Sharma, Ittehad Ul Mulk, David Li, Naod F Belay, Muhammad Afzal, Ameer Mustafa Farrukh, Muhammad Asad, Abdul Baqi, Bader Semakieh
BACKGROUND: Hypertension has significantly contributed to morbidity and mortality, necessitating effective management. Angiotensin receptor blockers (ARBs) have emerged as a cornerstone in hypertension treatment. Azilsartan, a relatively recent addition to the ARB family, offers unique characteristics, including prodrug activation. This systematic review and meta-analysis aimed to evaluate Azilsartan's role in reducing clinical blood pressure compared to other ARBs and determine the most effective dosage...
February 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38184805/azilsartan-attenuates-3-nitropropinoic-acid-induced-neurotoxicity-in-rats-the-role-of-i%C3%A4-b-nf-%C3%A4-b-and-keap1-nrf2-signaling-pathways
#3
JOURNAL ARTICLE
Hend A Hamouda, Rabab H Sayed, Nihad I Eid, Bahia M El-Sayeh
Huntington's disease (HD) is an autosomal-dominant neurodegenerative disorder characterized by motor, psychiatric and cognitive symptoms. Injection of 3-nitropropionic acid (3-NP) is a widely used experimental model for induction of HD. The current study aimed to inspect the potential neuroprotective properties of azilsartan (Azil), an angiotensin II type 1 receptor blocker (ATR1), in 3-NP-induced striatal neurotoxicity in rats. Rats were randomly allocated into five groups and treated for 14 days as follows: group I received normal saline; group II received Azil (10 mg/kg, p...
January 7, 2024: Neurochemical Research
https://read.qxmd.com/read/38158926/-sartans-in-the-treatment-of-arterial-hypertension-focus-on-telmisartan-and-azilsartan-a-review
#4
JOURNAL ARTICLE
V D Zakiev, Y V Kotovskaya, O N Tkacheva
The activity of the renin-angiotensin-aldosterone system is one of the main pathogenetic mechanisms underlying cardiovascular diseases at all stages of the cardiovascular continuum. This article discusses the role of telmisartan and azilsartan as the most powerful sartans in modern cardiology. Azilsartan and especially telmisartan have a significant organoprotection and are superior to other antihypertensive drugs in terms of lowering blood pressure. However, the effect of azilsartan on hard endpoints has not been studied while the efficacy of telmisartan on hard endpoints has been evaluated in plenty clinical trials including 3 large randomized clinical trials with several thousand patients...
November 3, 2023: Terapevticheskiĭ Arkhiv
https://read.qxmd.com/read/37991525/effect-of-azilsartan-on-myocardial-remodeling-after-acute-myocardial-infarction
#5
RANDOMIZED CONTROLLED TRIAL
Jing Wang, Ying Ding, Yi-Ren Yao, Hong-Yang Liu, Yang Gu
PURPOSE: To investigate the effect of azilsartan on myocardial remodeling after acute myocardial infarction (AMI). METHODS: A total of 200 AMI patients under percutaneous coronary intervention (PCI) were selected from the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University from Jan 2021 to Dec 2021. The subjects were randomly divided to take either azilsartan or benazepril. Serum C1q tumor necrosis factor-associated protein 1 (CTRP1) levels were detected in all subjects after admission, and the indices of left ventricular end-diastolic volume (LVEDV), left ventricular end-diastolic diameter (LVEDD), and left ventricular ejection fraction (LVEF) were measured by using echocardiography...
February 2024: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/37908315/curative-effect-of-ad-mscs-against-cisplatin-induced-hepatotoxicity-in-rats-is-potentiated-by-azilsartan-targeting-oxidative-stress-mapk-and-apoptosis-signaling-pathways
#6
JOURNAL ARTICLE
Amany Abdlrehim Bekhit, Olivia N Beshay, Michael A Fawzy, Sara Mohamed Naguib Abdel-Hafez, Gaber El-Saber Batiha, Farid S Ataya, Moustafa Fathy
Despite its clinical value, cisplatin (CISP) is complicated by marked hepatotoxicity via inducing oxidative stress, inflammatory, and apoptotic pathways. This study aims to explore the protective impact of azilsartan (AZIL), an antihypertensive drug, in addition to adipose tissue-derived mesenchymal stem cells (AD-MSCs) on CISP-induced hepatotoxicity. After characterization and labeling of AD-MSCs by PKH26 dye, 54 Wistar male albino rats were randomly divided into nine groups: I (CONT), II (AZIL.H), III (CISP), IV (CISP + AZIL...
2023: Stem Cells International
https://read.qxmd.com/read/37532820/efficacy-of-azilsartan-on-left-ventricular-diastolic-dysfunction-compared-with-candesartan-j-taste-randomized-controlled-trial
#7
JOURNAL ARTICLE
Shin Ito, Hiroyuki Takahama, Masanori Asakura, Yukio Abe, Masayoshi Ajioka, Toshihisa Anzai, Takuo Arikawa, Takaharu Hayashi, Yorihiko Higashino, Shinya Hiramitsu, Noriaki Iwahashi, Chisato Izumi, Kazuo Kimura, Koichiro Kinugawa, Hidetaka Kioka, Young-Jae Lim, Ken Matsuoka, Satoshi Matsuoka, Hirohiko Motoki, Sunao Nakamura, Takafumi Nakayama, Akihiro Nomura, Taishi Sasaoka, Shin Takiuchi, Shigeru Toyoda, Tomoya Ueda, Tetsuya Watanabe, Akira Yamada, Masayoshi Yamamoto, Takashi Sozu, Masafumi Kitakaze
Characterized by ventricular and vascular stiffness, heart failure with preserved ejection fraction (HFpEF) has led to high morbidity and mortality. As azilsartan is an angiotensin receptor blocker with the highest myocardial and vascular affinities, azilsartan may improve the left ventricular (LV) diastolic function in patients with hypertension and either HFpEF or HF with mildly reduced ejection fraction (HFmrEF) more than candesartan. In this randomized, open-label trial, we randomly assigned 193 hypertensive patients with HF and LV ejection fraction ≥ 45% to 20 mg of azilsartan (n = 95) or 8 mg of candesartan (n = 98), once daily for 48 weeks...
August 2, 2023: Scientific Reports
https://read.qxmd.com/read/37062187/azilsartan-ameliorates-skeletal-muscle-wasting-in-high-fat-diet-hfd-induced-sarcopenic-obesity-in-rats-via-activating-akt-signalling-pathway
#8
JOURNAL ARTICLE
Priyanka Prajapati, Anand Kumar, Jiten Singh, Shubhini A Saraf, Sapana Kushwaha
An association between the loss of skeletal muscle mass and obesity in the geriatric population has been identified as a disease known as sarcopenic obesity. Therefore, therapeutic/preventive interventions are needed to ameliorate sarcopenia. The present study investigates the effect of azilsartan (AZL) on skeletal muscle loss in High-Fat Diet (HFD)-induced sarcopenic obese (SO) rats. Four- and fourteen-months male Sprague Dawley rats were used and randomized in control and azilsartan treatment. 14 months animals were fed with HFD for four months and labeled as HFD-fed SO rats...
April 11, 2023: Archives of Gerontology and Geriatrics
https://read.qxmd.com/read/37033509/comparison-of-efficacy-and-safety-of-azilsartan-and-amlodipine-combination-versus-telmisartan-and-amlodipine-combination-in-hypertensive-patients-a-non-inferiority-trial
#9
JOURNAL ARTICLE
Ashish Dash, Bikash R Meher, Biswa M Padhy, Rashmi R Mohanty, Amruta Tripathy
Introduction Hypertension (HTN) is one of the most common conditions encountered in daily practice in hospitals. Combination therapy is mostly initiated in the management of HTN when target blood pressure is not achieved with monotherapy. There are few studies comparing the antihypertensive effect of a combination of azilsartan and amlodipine with a combination of amlodipine and other angiotensin receptor blockers (ARBs), however, the results are contradictory. The objective of this study was to compare the efficacy and safety of the azilsartan and amlodipine combination versus the telmisartan and amlodipine combination in hypertensive patients...
March 2023: Curēus
https://read.qxmd.com/read/36930951/azilsartan-suppresses-the-antiapoptotic-biomarker-and-pro-inflammatory-cytokines-in-rat-model-of-cisplatin-induced-retinal-and-optic-nerve-toxicity
#10
JOURNAL ARTICLE
Noor Majid Raheem, Naza Mohammed Ali Mahmood
BACKGROUND: The local renin-angiotensin system has been discovered in the eyes; thus, this study evaluates the Azilsartan effect in the retina and optic nerve toxicity induced by Cisplatin in vivo. METHODOLOGY: Forty-eight male rats were randomly assigned into six groups of 8 animals. Group 1 was healthy control that received 0.5 mL/day of 0.5% carboxymethyl cellulose (CMC) orally (PO). Group 2 received a single dose of the 7.0 mg/kg CIS intraperitoneally with 0...
2023: Human & Experimental Toxicology
https://read.qxmd.com/read/35592072/gastroprotective-effect-of-azilsartan-through-ameliorating-oxidative-stress-inflammation-and-restoring-hydroxyproline-and-gastrin-levels-in-ethanol-induced-gastric-ulcer
#11
JOURNAL ARTICLE
Renas Raouf Hama Amin, Tavga Ahmed Aziz
Objective: The present study was designed to evaluate the possible gastroprotective effects of different doses of azilsartan in ethanol-induced gastric ulcers in rats. Methodology: Forty-eight male adult Wistar rats were used and allocated randomly into four groups: negative control treated with distilled water, positive control treated with ethanol, lansoprazole treated group, and azilsartan (1mg, 5mg, and 10mg/kg) treated group. The treatment protocol was for 15 days, and all the groups except for the negative control group received 1mL of ethanol on the last day 1hr before scarification...
2022: Journal of Inflammation Research
https://read.qxmd.com/read/35350513/comparative-study-of-the-effects-of-azilsartan-and-telmisartan-on-insulin-resistance-and-metabolic-biomarkers-in-essential-hypertension-associated-with-type-2-diabetes-mellitus
#12
JOURNAL ARTICLE
Bikash R Meher, Rashmi R Mohanty, Jyoti P Sahoo, Monalisa Jena, Anand Srinivasan, Biswa M Padhy
Introduction The complex interplay between the autonomic nervous system, renin-angiotensin-aldosterone system (RAAS), and immunity contributes to the pathogenesis of hypertension in diabetes mellitus. The objective of this study was to investigate and compare the effect of azilsartan and telmisartan on insulin resistance and metabolic biomarkers in patients with both hypertension and type 2 diabetes mellitus. Methods The present study was a prospective, randomized, active-controlled, open-label, parallel-group clinical trial...
February 2022: Curēus
https://read.qxmd.com/read/33693183/comparative-effectiveness-of-angiotensin-ii-receptor-blockers-in-patients-with-hypertension-in-japan%C3%A3-systematic-review-and-network-meta-analysis
#13
JOURNAL ARTICLE
Tadashi Nakajima, Akinori Oh, Shun Saita, Takuo Yoshida, Mitsuru Ohishi, Nobuhiro Nishigaki
Background: Angiotensin II receptor blockers (ARBs) are widely used for the management of hypertension in Japan; however, comparative efficacy data within the ARB drug class remain limited. Methods and Results: This systematic literature review identified randomized controlled trials (RCT) indexed in PubMed and Ichushi in Japanese patients with hypertension receiving ARB monotherapy (azilsartan, candesartan cilexetil, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, valsartan) in at least 1 arm...
September 18, 2020: Circulation reports
https://read.qxmd.com/read/33677450/stronger-effect-of-azilsartan-on-reduction-of-proteinuria-compared-to-candesartan-in-patients-with-ckd-a-randomized-crossover-trial
#14
JOURNAL ARTICLE
Takaichi Suehiro, Kazuhiko Tsuruya, Hisako Yoshida, Hiroaki Tsujikawa, Shunsuke Yamada, Shigeru Tanaka, Akihiro Tsuchimoto, Masahiro Eriguchi, Kiichiro Fujisaki, Kumiko Torisu, Toshiaki Nakano, Takanari Kitazono
INTRODUCTION: Angiotensin receptor blockers (ARBs) are preferably used in hypertensive patients with CKD. Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood. We compared the antiproteinuric effect of azilsartan and candesartan in CKD patients in an open-label, randomized, crossover trial. METHODS: A total of 111 patients were treated with 20 mg of azilsartan daily for 2 months as a run-in period. After the run-in period, patients were randomized into 2 arms and received either 20 mg of azilsartan or 8 mg of candesartan daily for 3 months in a crossover trial...
March 5, 2021: Kidney & Blood Pressure Research
https://read.qxmd.com/read/33609077/is-the-newest-angiotensin-receptor-blocker-azilsartan-medoxomil-more-efficacious-in-lowering-blood-pressure-than-the-older-ones-a-systematic-review-and-network-meta-analysis
#15
JOURNAL ARTICLE
Ji-Guang Wang, Miao Zhang, Ying-Qing Feng, Chang-Sheng Ma, Tzung-Dau Wang, Zhi-Ming Zhu, Kazuomi Kario
Angiotensin-receptor blockers are often considered insufficiently efficacious in reducing blood pressure. However, newer angiotensin-receptor blockers may be more effective than the older ones. A network meta-analysis was performed to compare the efficacy of various angiotensin-receptor blockers in reducing office and ambulatory blood pressure in hypertensive patients. Relevant literature was searched from English and Chinese databases for randomized controlled trials involving angiotensin-receptor blockers in hypertension...
May 2021: Journal of Clinical Hypertension
https://read.qxmd.com/read/33527809/evaluation-of-the-efficacy-and-safety-of-azilsartan-in-adult-patients-with-essential-hypertension-a-randomized-phase-iii-clinical-study-in-india
#16
RANDOMIZED CONTROLLED TRIAL
Shubhadeep Sinha, Sreenivasa Chary, Mohan Reddy Bandi, Pankaj Thakur, Leela Talluri, Vijay Kumar Reddy, Manish Agarwal, Sunil Naik K, Azilsartan Study In Indian Adult Patients Of Essential Hypertension Investigators Azilehi Group
BACKGROUND: Globally, women and men over the age of 25 years suffer from hypertension, the need for new treatment strategies to treat hypertension is due to the multi-faceted nature of the disease. Lack of optimal blood pressure control can lead to multiple complications. Therefore, this phase 3 study was conducted to assess the efficacy, safety and tolerability of potential product azilsartan hydrochloride for reduction in blood pressure in Indian patients with essential hypertension...
February 2021: Journal of the Association of Physicians of India
https://read.qxmd.com/read/32899104/a-phase-3-double-blind-randomized-consort-compliant-study-of-azilsartan-medoxomil-compared-to-valsartan-in-chinese-patients-with-essential-hypertension-erratum
#17
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
September 4, 2020: Medicine (Baltimore)
https://read.qxmd.com/read/32769878/a-phase-3-double-blind-randomized-consort-compliant-study-of-azilsartan-medoxomil-compared-to-valsartan-in-chinese-patients-with-essential-hypertension
#18
JOURNAL ARTICLE
Jiahui Wu, Xin Du, Qiang Lv, Zhanquan Li, Zeqi Zheng, Yong Xia, Chengchun Tang, Zhuhua Yao, Jun Zhang, Mingzhi Long, Michie Hisada, Jingtao Wu, Wei Zhou, Changsheng Ma
BACKGROUND: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has a well-characterized efficacy and safety profile in patients with hypertension. AZL-M is approved for use in over 40 countries globally; however, it is not yet approved in China. Therefore, a phase 3 registration study to assess the efficacy (antihypertensive effect), safety, and tolerability of AZL-M compared with valsartan in Chinese patients with essential hypertension was undertaken. METHODS: This multicenter, double-blind, randomized, 8-week phase 3 study compared AZL-M with valsartan in Chinese patients aged ≥18 years with essential hypertension...
August 7, 2020: Medicine (Baltimore)
https://read.qxmd.com/read/32587489/efficacy-and-safety-of-azilsartan-medoxomil-and-telmisartan-in-hypertensive-patients-a-randomized-assessor-blinded-study
#19
JOURNAL ARTICLE
Megha Garg, Geetesh Manik, Alok Singhal, V K Singh, Rohit K Varshney, Aseem Sethi
Background: Few studies have compared the safety and efficacy of azilsartan medoxomil (AZL-M) and telmisartan in hypertensive patients, especially using ambulatory blood pressure monitoring (ABPM). Objective: The objective of this study was to compare the efficacy and safety profile of AZL-M and telmisartan in hypertensive patients using ABPM and clinic blood pressure (BP) monitoring. Materials and Methods: This prospective, randomized, open-label, blinded endpoint, parallel-arm study included 700 patients, aged 18-70 years, with clinic and 24-h mean ambulatory systolic BP (SBP) of 150-180 mmHg and 130-170 mmHg, respectively...
May 2020: Saudi Journal of Medicine & Medical Sciences
https://read.qxmd.com/read/31827918/systematic-review-with-network-meta-analysis-comparative-efficacy-and-safety-of-combination-therapy-with-angiotensin-ii-receptor-blockers-and-amlodipine-in-asian-hypertensive-patients
#20
JOURNAL ARTICLE
Dae Wook Lee, Mira Jung, Hye Won Wang, Zainah Khan, Philippe Pinton
BACKGROUND: Hypertension (HTN) is the leading risk factor for cardiovascular mortality globally. The WHO estimates a 60% increase in Asian HTN patients between 2000 and 2025. Numerous studies have compared safety and efficacy between antihypertensive classes, but in-class comparisons of angiotensin II receptor blockers (ARBs) in combination therapy (CT) (fixed-dose combination or dual combination) with a calcium channel blocker (CCB) are lacking in Asia. OBJECTIVE: To compare the efficacy and safety of the various ARB-amlodipine CTs and amlodipine (AML) monotherapy for treatment of HTN in Asian population...
2019: International Journal of Hypertension
keyword
keyword
161966
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.